Recombinant anti-HER2 humanized monoclonal antibody complex

重组抗HER2人源化单克隆抗体组合物

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRecombinant anti-HER2 humanized monoclonal antibody complex
Drug Alias Name注射用重组抗HER2人源化单克隆抗体组合物B-002
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsMetastatic breast cancerBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Pharmaceuticals Holding Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Pharmaceuticals Holding Co LtdShanghai Crosslink Pharmaceutical R & D Co Ltd
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A